Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
10 studies found for:    AMYOTROPHIC LATERAL SCLEROSIS 3
Show Display Options
Rank Status Study
1 Active, not recruiting Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: MCI-186;   Drug: Placebo;   Drug: MCI-186 in open label phase
2 Completed Phase 3 Study of Dexpramipexole in ALS
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Dexpramipexole;   Drug: Placebo
3 Terminated Phase 3 Extension Study of Dexpramipexole in ALS
Condition: Amyotrophic Lateral Sclerosis
Intervention: Drug: Dexpramipexole
4 Completed A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis
Intervention: Drug: TCH346
5 Recruiting Clinical Trial Phase Multicentric I/II to Evaluate Safety in Patients With Amyotrophic Sclerosis Lateral
Condition: Amyotrophic Lateral Sclerosis
Interventions: Other: Intravenous administration of placebo;   Drug: Intravenous administration of 1 million of MSC;   Drug: Intravenous administration of 2 million of MSC;   Drug: Intravenous administration of 4 million of MSC
6 Completed Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Memantine (Ebixa);   Drug: riluzole;   Drug: Placebo
7 Completed Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: MCI-186;   Drug: Placebo of MCI-186
8 Completed High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis
Interventions: Dietary Supplement: Oxepa;   Dietary Supplement: Jevity 1.5;   Dietary Supplement: Jevity 1.0
9 Recruiting Therapy in Amyotrophic Lateral Sclerosis With Memantine at 20 mg BID (TAME)
Conditions: Amyotrophic Lateral Sclerosis;   Frontal Temporal Dementia
Interventions: Drug: Memantine;   Drug: Placebo (for Memantine)
10 Recruiting Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects
Condition: Sialorrhea
Intervention: Drug: MYOBLOC

Indicates status has not been verified in more than two years